These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 21083648)

  • 1. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma.
    Kähler KC; Hauschild A
    J Dtsch Dermatol Ges; 2011 Apr; 9(4):277-86. PubMed ID: 21083648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management.
    Kaehler KC; Piel S; Livingstone E; Schilling B; Hauschild A; Schadendorf D
    Semin Oncol; 2010 Oct; 37(5):485-98. PubMed ID: 21074064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of immune-related adverse events and kinetics of response with ipilimumab.
    Weber JS; Kähler KC; Hauschild A
    J Clin Oncol; 2012 Jul; 30(21):2691-7. PubMed ID: 22614989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?
    Ménard C; Ghiringhelli F; Roux S; Chaput N; Mateus C; Grohmann U; Caillat-Zucman S; Zitvogel L; Robert C
    Clin Cancer Res; 2008 Aug; 14(16):5242-9. PubMed ID: 18698043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma.
    Kähler KC; Hassel JC; Heinzerling L; Loquai C; Mössner R; Ugurel S; Zimmer L; Gutzmer R;
    J Dtsch Dermatol Ges; 2016 Jul; 14(7):662-81. PubMed ID: 27373241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical development of the anti-CTLA-4 antibody tremelimumab.
    Ribas A
    Semin Oncol; 2010 Oct; 37(5):450-4. PubMed ID: 21074059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.
    Weber J
    Semin Oncol; 2010 Oct; 37(5):430-9. PubMed ID: 21074057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma.
    Agarwala SS
    Melanoma Res; 2010 Feb; 20(1):1-10. PubMed ID: 19952852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
    Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
    Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.
    Wolchok JD; Saenger Y
    Oncologist; 2008; 13 Suppl 4():2-9. PubMed ID: 19001145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune modulation in melanoma and advanced cancer therapy: anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibodies.
    Esper P
    Clin J Oncol Nurs; 2009 Oct; 13(5):547-54. PubMed ID: 19793711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma.
    Reuben JM; Lee BN; Li C; Gomez-Navarro J; Bozon VA; Parker CA; Hernandez IM; Gutierrez C; Lopez-Berestein G; Camacho LH
    Cancer; 2006 Jun; 106(11):2437-44. PubMed ID: 16615096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues.
    Phan GQ; Weber JS; Sondak VK
    Ann Surg Oncol; 2008 Nov; 15(11):3014-21. PubMed ID: 18716842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.
    Boasberg P; Hamid O; O'Day S
    Semin Oncol; 2010 Oct; 37(5):440-9. PubMed ID: 21074058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent.
    Jaber SH; Cowen EW; Haworth LR; Booher SL; Berman DM; Rosenberg SA; Hwang ST
    Arch Dermatol; 2006 Feb; 142(2):166-72. PubMed ID: 16490844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming immunological tolerance to melanoma: Targeting CTLA-4.
    Hodi FS
    Asia Pac J Clin Oncol; 2010 Mar; 6 Suppl 1():S16-23. PubMed ID: 20482528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer.
    Ribas A; Hanson DC; Noe DA; Millham R; Guyot DJ; Bernstein SH; Canniff PC; Sharma A; Gomez-Navarro J
    Oncologist; 2007 Jul; 12(7):873-83. PubMed ID: 17673618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
    Graziani G; Tentori L; Navarra P
    Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
    Hoos A; Ibrahim R; Korman A; Abdallah K; Berman D; Shahabi V; Chin K; Canetta R; Humphrey R
    Semin Oncol; 2010 Oct; 37(5):533-46. PubMed ID: 21074069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.
    O'Day SJ; Hamid O; Urba WJ
    Cancer; 2007 Dec; 110(12):2614-27. PubMed ID: 18000991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.